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ABSTRACT
Background: Prostate cancer (PCa) is one of the most widespread cancers diagnosed in
men in the United States and is the second leading cause of cancer-related deaths
worldwide. PCa will be a major cancer-related burden both socially and economically in
the near future. It has been shown that dietary intake of natural anti-inflammatory agents
are capable of inhibiting cancer progression, but due to the nature of dietary studies it is
difficult to accurately conclude that diet is capable of impacting chronic diseases and
mortality. This systematic review aims to collect and evaluate literature focused on PCa
progression and the natural anti-inflammatory agents of lycopene and the Mediterranean
diet (MedD).
Data Sources: An electronic search included the following databases: PUBMED,
EBSCOhost Web, Scopus and clinical trials registry platforms were used to survey the
important literature.
Study Selection: Study inclusion criteria were as follows: 1) uniform form of
measurement for evaluating the risk of PCa/ current state of PCa in patients; 2) patients
treated in a clinical or observational setting; 3) an experimental group in which subjects
clearly underwent an intervention focused on preventing or reducing PCa initiation or
progression; 4) a clearly defined control group in which subjects received either a
placebo or standard care therapy; and 5) an outcome measure assessing the risk or current
state of PCa.
Data Extraction: For randomized control trials a qualitative analysis was done to collate
and summarize effects of identified interventions according to the recommended
methodology from the Cochrane Handbook. For all other types of studies (Cohort
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Studies, Case-control studies, a Cross-sectional studies) a rubric of criteria was created
and used for analysis.
Data Synthesis: There were 24 randomized control trials that met all inclusion and no
exclusion criteria for the search concerning lycopene and PCa. There was 1 randomized
control trial that met all inclusion and no exclusion for the search concerning the MedD
and PCa. All studies had some concern for bias; therefore, the Cochrane risk bias tool as
well as a rubric of criteria was used.
Conclusions: Given the fact that there were not many high-quality studies done
regarding the effect of lycopene on PCa initiation and progression. Based on the current
literature there is not enough evidence to conclude that Lycopene or the MedD is able to
affect either PCa initiation or progression. As of now there are not enough high-quality
clinical investigations done to show evidence that the Lycopene or the MedD is capable
of inhabiting initiation or proliferation of PCa. In the future, more high-quality clinical
investigations will need to be done before making this conclusion.
Keywords: prostate cancer, lycopene, Mediterranean diet, systematic review.
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INTRODUCTION
1.1 Background: Prostate Cancer
Prostate cancer (PCa) is one of the most diagnosed cancers in men in the United
States and the second leading cause of cancer-related deaths worldwide [1]. Since over
60% of PCa cases occur in men over 65 years old and this population will continue to
increase consistently in the coming years, PCa will be a major cancer-related burden both
socially and economically in the foreseeable future [1]. Compared to most other cancers,
PCa progression is much slower, and therefore one of the most common approaches for
early and low-risk PCa is non-invasive active surveillance [2], which can be continued
until progression occurs and more aggressive treatments such as surgery or radiotherapy
then become essential [2]. In some cases, PCa progression can be so slow that the patient
will never experience any symptoms and therefore no need to undergo any treatment.
For advanced PCa, the common treatments are radical prostatectomy,
radiotherapy, chemotherapy, androgen-deprivation therapy (ADT), or a combination of
therapies. The objective of ADT is to repress the androgen-induced androgen receptor
(AR) signaling pathway which can be implemented by either physical or chemical
castration [3]. Most PCa is responsive to ADT. But it is common for the PCa to become
castration-resistant PCa (CRPC) [4] resulted from either constitutively active AR variants
or AR activation by other agents [5]. For CRPC, the treatment is commonly a
combination of ADT with a second-line hormonal therapy including antiandrogen,
androgen synthesis inhibitor, or an AR signaling inhibitor [6]. CRPC is likely to occur in
ADT-treated patients within 3 years [7] and is characterized by poor prognosis and a
decreased quality of life [8,9]. On average, the survival time of patients with CRPC is 9-
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36 months but can vary due to the degree of metastatic status and severity of the disease
[8,10]. Some other treatment options for metastatic and CRPC are chemotherapy and
immunotherapy [11].
Compared to most other cancers, PCa is usually diagnosed later in life and often
progresses very slowly [2]. These two features make PCa a useful model when studying
natural agents since these agents usually have low toxicity and fewer side effects but take
a longer time for them to show the same effect as their pharmaceutical counterparts.
Studies have shown that natural anti-inflammatory agents have inhibitory effects on
cancer development and/or progression [12-14], suggesting that anti-inflammatory agents
such as Resveratrol [15], lycopene, monoterpenes, and many others [16] could be used as
either preventive or therapeutic reagents. Results from both cellular and animal studies
indicate that antioxidants may inhibit cancer development by lowering free radical
damage [17]. It has been shown that these natural agents are capable of affecting growth,
cell cycle progression, apoptosis, and hinder metastasis of various cancers including PCa
[12,18,19]. Therefore, natural anti-inflammatory agents are valuable as a prospective
treatment and therapy for PCa, either by themselves or in combination with other drugs.
Compared to that obtained from a randomized clinical trial (RCT), results from
observational studies are often controversial. There are nine reported RCTs regarding
dietary antioxidant supplements in PCa prevention [17]. However, the overall findings
failed to show conclusive evidence whether or not dietary antioxidants are beneficial in
cancer prevention [17]. One of the reasons could be the results of different interventions
used. When studying the dietary effects, the intervention often either be given as purified
chemicals or through foods and diet (which includes different mixtures of vitamins and
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minerals). It is conceivable that the type of intervention used can affect the results
greatly.

Figure 1.1.

Different Treatment Options Available for PCa, showing in red the potential places
of impact of natural anti-inflammatory agents

1.2 Effects of Natural Anti-Inflammatory Agents on Prostate Cancer: Lycopene
One of the natural agents that has been studied in the inhibition of initiation and
progression of PCa is lycopene. Lycopene is an essential nutrient needed for plants and
has antioxidant characteristics, which is also the pigment that gives red and pink fruits
(ex. tomatoes and watermelon) their colors [20]. The use of antioxidants, such as
lycopene, has been copiously studied and shown that they are capable of inhibiting the
harmful consequences of oxidation in both animal and cell culture. The protective role of
lycopene in PCa has been studied substantially [21, 22]. It has been shown that
lycopene’s inhibitory effect on PCa in tissue culture, in vitro systems [23-26] as well as
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mouse model [27-30] by targeting various cell mechanisms such as NF-κB signaling
pathway [31], RAR/PPARs signaling [32], SIRT1 signaling pathway [33], and p53 tumor
suppressor pathways [34]. However, epidemiological studies have shown different
results. For example, observational epidemiological studies have led to conflicting results
with some findings lycopene inhibits the initiation and proliferation of PCa [14, 35-37]
while other reports conclude that no association was established [38-42]. Within the
different types of clinical trials, observational studies have the lowest strength of
conclusion and meta-analysis/systemic reviews have the strongest strength of conclusion.
Since observational studies lead to conflicting results, an analysis of previous metaanalysis/systemic reviews was then conducted. A meta-analysis combines the results of
multiple studies and performs a statistical analysis while a systemic review answers a
defined research question by collecting and summarizing all empirical evidence that fits
pre-specified eligibility criteria. There are 9 previous meta-analysis/systemic reviews [4351] regarding lycopene and PCa. When analyzing the reason for these contradictory
results, the methodology must be carefully reviewed. The largest methodological
discrepancy between these nine studies is the use of observational studies versus
randomized control trials (RCT).
When further investigating these differences in methodology, one of the most
noticeable is the classifications of lycopene. Some studies focused on diet, while some
focused on supplementary intake. The reason that these different classifications of
lycopene are important due to their bioavailability. Previous research has shown a
slightly inverse association for higher intake of cooked tomato products vs raw tomato
products [52, 53]. The reason for this discrepancy could be due to the fact that lycopene
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is a lipophilic molecule and therefore cooking may increase its bioavailability [21, 54].
Another part of the methodology that should be noted is the different ways of data
collection. Since many studies used various data collection methods by analyzing the
validity and reliability of these methods it could greatly help when trying to determine the
reason for these contradictory results. Other factors need to be considered are
measurement error, without considering pertinent information (ex. family history), and
biases such as recall bias and residual confounding [47, 50].

Figure 1.2.

Effects of Lycopene on PCa progression

1.3 The Mediterranean Diet and Prostate Cancer:
All cancers, including PCa, are known to be affected by diet. In fact, only 5-10%
of cancer cases are due to genetic causes while 90-95% can be attributed to environment
and lifestyle [55]. In the United States, approximately 30-35% of cancer-related deaths
can be attributed to diet [56]. Therefore, diet is extremely important when researching
possible preventative and inhibitory cancer treatments.
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Figure 1.3.

Age-standardized incidence and mortality of PCa in selected countries.
Graph from Kimura et al. [57]

Asian countries have the lowest incidence and mortality for PCa (Figure 1.3).
This can be contributed to multiple factors, some being possible reasons for this are, lack
of screening, timing of diagnosis, awareness of the disease, access to health care, and diet
[57]. Multiple studies concluded that Asian immigrants residing in European countries
and North America had a much higher PCa incidence than in their countries of origin [57,
58]. This data helps further explain the importance of die and lifestyle in the development
of PCa. Due to the lack of screening and limited data availability in this region, this
systematic review will not be focusing on PCa incidence or progression in Asian
countries. The second region with the lowest PCa incidence and progression is Europe
(Figure 1.3 and 1.4). One factor that might help explain these lower rates of incidence
and progression could be diet. Expanding on the importance of diet in PCa, it has been
demonstrated that populations occupying the Mediterranean area (Southern Europe) have
a decreased incidence of cancer in comparison to Northern Europe and the US; one
reason for this might be their healthier dietary habits [56]. The dietary habits of this
region are referred to as the Mediterranean diet (MEdD). Even though the graph (Figure
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1.4) shows that Central and Eastern Europe have a lower PCa incidence, this review will
be focusing on Southern Europe because multiple components of the MedD have been
suggested to be capable of inhibiting PCa incidence and progression.

Figure 1.4.

PCa incidence worldwide. Taken from Zhang et al. [59]

The MedD has been suggested to be responsible for the lower cancer incidences
in regions in which people follow this diet [60, 61]. The foundation of the MedD is based
on the dietary habits of Spain, Italy, and Greece in the 1960s [55]. The MedD is
distinguished by a large intake of plant-based foods. These foods include vegetables,
fruits, nuts, legumes, and many whole grain products. The MedD also involves a regular
intake of fish, seafood, and a moderate alcohol consumption, usually in the form of red
wine. Fat is typically consumed through olive oil, therefore leading to a low saturated
fatty acid intake. Foods such as eggs, high-fat dairy products and red and processed meat
are consumed in low quantities in the MedD [62].
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A pooled analysis of individual elements of the MedD has shown that the
protective properties are most associated with fruits, vegetables, and whole grains [62].
There have been many previous observational studies performed. These studies lead to
conflicting results, and due to the considerable bias in these studies (ex. Selection bias)
and the short comes is the methodology (ex. Surveys and questionaries). Therefore, this
review will primarily be focusing on systemic reviews and meta-analysis. There are five
previously conducted systematic review and meta-analysis. All of them used
observational studies most likely due to the cost of the high-quality RCT. Of these five,
four (4/5) found that the MedD was capable of reducing PCa incidence [62-65] while one
(1/5) [66] found that there was insufficient evidence to determine if the MedD was
capable of reducing PCa incidence. Since the results of these meta-analyses yielded
contradicting results, under very similar conditions (ex. similar databases, data collection
performed around the same time, and similar statistical tests) the question is raised of
why and how this occurred.
One of the reasons that these systematic reviews and meta-analyses yielded
contradictory results could be due to their methodological limitations. All of the studies
were observational studies which relied on a food frequency questionnaire. The results
from these questionnaires might not accurately represent a diet that is capable to impact
chronic diseases and mortality [62]. Another methodological limitation is that since there
is no universal definition of the MedD, is it extremely difficult to make any conclusions
regarding the effect of the MedD in PCa. Other limitations of diet-based studies may
include publication bias, misclassification bias and lack of eligible studies [67]. In order
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to eliminate these biases in this review, only RCT will be used since they have the
strongest clinical strength of conclusion.

Figure 1.5.

The MedD Food Pyramid

1.4 Thesis Aims
Previous meta-analysis and systematic reviews regarding lycopene’s inhibitory
effect on PCa have yielded varying results, the potential benefits of lycopene are still
uncertain. Since these large-scale studies have the strongest strength of conclusion and
they produced various results, this systemic review will provide a deeper investigation of
these studies, in hopes that the cause of these discrepancies can be explained. This
systemic review will also analyze the bias present in both observation and RCT with the
purpose of determining the quality and bias. If this review finds that lycopene is be
beneficial to inhibiting PCa inhibition or progression, then the clinical use of lycopene for
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PCa patients is recommended. However, if this review is unable to conclude that
lycopene is be beneficial to inhibiting PCa inhibition or progression, then the clinical use
of lycopene for PCa patients would not be recommended.
Previous large-scale studies regarding the inhibitory effects of the MedD on PCa
have also led to various results. All of these previous studies only used observational
study data inherent with many potential biases. If this review concludes that the MedD is
beneficial to inhibiting PCa inhibition or progression, then the clinical use of the MedD
for PCa patients is recommended. However, if this review is not able to conclude that
MedD is beneficial to inhibiting PCa inhibition or progression, then the clinical use of the
MedD for PCa patients would not be recommended.
I first collected, categorized, and reviewed pre-existing studies. The ones that
meet all inclusion and no exclusion were further analyzed. The analyses include reporting
the levels of bias (ie. High risk or low risk) in each study. It will also help identify what
type of future research needs to be done. The hypothesis that MedD and lycopene are
protective against PCa will be tested. The results of this review will either help justify or
refute the use of both the MedD and lycopene in the inhibition of initiation and
progression of PCa.
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METHODS
1. Identification of the Related Studies
An electronic search was conducted with the following databases: PUBMED,
EBSCOhost Web, and Scopus. The search terms included the key words of PCa, PCa
prevention, lycopene, and the MedD. The terms were selected based on the common key
words seen in previously published systematic reviews and meta-analysis focusing on the
PCa and Lycopene [47,50,51,68] and PCa and the MedD [62,67,69]

In order to collect possible unpublished data from the clinical trials, an electronic search
of the databases was done. These databases included the US National Library of
Medicine, ClinicalTrials.gov and the World Health Organization, International Clinical
Trials Registry Platform were also included. An unpublished clinical trial to be
considered for this critical analysis, it must already have subjects enrolled which is
specifically indicated on the database.

2. Selection Criteria for Previous Randomized Control Studies: Inclusion and
Exclusion
All human adult male interventional trials demonstrating the effects lycopene and the
MedD on PCa were considered for selection. In order for a study to be included, they
must have a 1) uniform form of measurement* for evaluating the risk of PCa/current state
of PCa in patients; 2) patients treated in a clinical or observational setting; 3) an
experimental group in which subjects clearly underwent an intervention focused on
preventing or reducing PCa initiation or progression; 4) a clearly defined control group in
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which subjects received either a placebo or standard care therapy; and 5) an outcome
measure assessing the risk or current state of PCa.

* Examples of uniform form of measurement:
•

TNM Classification of Malignant Tumors (TNM)

•

Prostate Specific Antigen (PSA) Levelsà

•

Gleason Score à This score is based on how much the cancer looks like healthy
tissue when viewed under a microscope. Less aggressive tumors generally look
more like healthy tissue. Cancer cells that look similar to healthy cells receive a
low score.

•

Mortality

•

IGF-1 Levels à IGF‐1 has been shown to promote cancer development by
inhibiting apoptosis and stimulating cell proliferation

à It should be noted that multiple studies revealed that when examining nutritional
effects, PSA levels are not as sensitive as researchers once assumed. Given this
knowledge, studies using PSA levels to measure dietary effects should be regarded as
lower-quality studies [43,70-72].
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2.1 Selection Criteria for Cohort Studies, Case-control Studies, Cross-Sectional and
Quasi-Experimental Studies: Inclusion and Exclusion
For the studies to be included, they must have 1) uniform form of measurement for
evaluating the risk of PCa/current status of PCa in patients; and 2) an outcome measure
assessing the risk or current status of PCa.

3. Study Categorization
Once studies were selected, they were categorized based on the type of study. The
categories are:
•

Randomized Control trials (RCTs)

•

Cohort Studies

•

Case-control studies

•

Cross-sectional studies

•

Quasi-Experimental studies

4. Assessment of Study Bias for Randomized Control Trials

Once the studies were selected using the inclusion and exclusion criteria and categorized
based on the type of study, ONLY RCTs were analyzed using the Cochrane Risk Bias
tool [73]. This tool determines the quality of the study and if the study has any bias.
Appendix F. Cochrane Risk of Bias Tool [73]
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Use the modified Cochrane Collaboration tool to assess risk of bias for randomized
controlled trials. Bias is assessed as a judgment (high, low, or unclear) for individual
elements from five domains (selection, performance, attrition, reporting, and other).
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4.1 Assessment of Study Bias for Cohort Studies, Case-control Studies, CrossSectional and Quasi-Experimental studies
For all other study categories (Cohort studies, Case-control studies, Cross-sectional, and
Quasi-Experimental studies). A rubric of criteria is used in order to assess the quality of
the study.
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Domain

Description

High Risk
of Bias

Low Risk of
Bias

Unclear
Risk of
Bias
Not
described in
sufficient
detail

Reviewer
Assessment

Study
Design

Describe
the
framework
and set of
methods
and
procedures
used to
collect and
analyze
data

Descriptive
Studies

Analytical
Studies

Confounding
Variables

Describe
what the
different
confounder
variables
were in the
experiments
as well as
how these
variables
were
controlled
and to what
extent.

Confounding
bias is due to
having
confounding
variables in
experimental
model.

Confounding
variables are
controlled
through,
randomization
and/or
matching
and/or
restriction

The
different
potential
confounding
variables
not
explained
and the
ways that
researchers
controlled
for
confounding
variables
were not
described in
sufficient
detail

High
Low
Unclear

Statistical
Experimental
Design

Efficient
procedure
for planning
statistical
experiments
therefore
the data
obtained
can be
analyzed to
yield valid
and
objective
results.

Poor
statistical
design
includes, too
few subjects,
performing
incorrect
statistical
tests, etc.

Statistical
experimental
design is
explained,
and all
statistical
tests are done
correctly

Not
described in
sufficient
detail

High
Low
Unclear

Reviewer
Comments

Article
Title

High
Low
Unclear

The below criteria are adapted from the Cochrane Risk Bias tool to fit the needs of this study. Not all research in this
area involves random controlled trials, and therefore would not meet all of the criteria from the original Cochrane Risk
Bias tool [73]. The risk bias tool was used as a reference for developing new criteria for purposes of the current study.
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Reporting
bias
Selective
reporting

Stated how the
possibility of
selective outcome
reporting was
examined by the
authors and what
was found

Reporting bias
due to selective
outcome
reporting

Selective
outcome
reporting
bias not
detected

Insufficient
informatio
n to
permit
High
judgment †

High
Low
Unclear

Other bias
Other
sources of
bias

Any important
concerns about
bias not addressed
above*

Bias due to
problems not
covered
elsewhere in the
table

No other bias
detected

High
Low
Unclear

Attrition
bias
Incomplet
e outcome
data

Described the
completeness of
outcome data for
each main
outcome,
including attrition
and exclusions
from the analysis.
Stated whether
attrition and
exclusions were
reported, the
numbers in each
intervention group
(compared with
total randomized
participants),
reasons for
attrition/exclusion
s where reported.

Attrition bias
due to amount,
nature or
handling of
incomplete
outcome data.

Handling of
incomplete
outcome data
was complete
and unlikely
to have
produced
bias

There may
be a risk of
bias, but
there is
either
insufficient
informatio
n to assess
whether an
important
risk of bias
exists or
insufficient
rationale or
evidence
that an
identified
problem
will
introduce
bias
Insufficient
reporting
of
attrition/ex
clusion
to permit
judgment
(e.g.,
number
randomize
d not
stated, no
reasons for
High
missing
data Low
provided)

High
Low
Unclear
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RESULTS
Randomized Control Trails (Lycopene)
Search and Selection
The initial database search identified 1768 studies relevant to lycopene and PCa.
But most of the studies (1,677) were excluded during the relevance screening (Fig 1).
Studies were excluded during the relevance screening secondary to 1) uniform form of
measurement* for evaluating the risk of PCa/ current status of PCa in patients, 2) missing
intervention or control arm, or 3) no outcome measure of PCa. A full manuscript review
was performed on the remaining 91 papers, resulting in 24 papers being included for final
analysis with a total of 1573 subjects. Table 1 displays the primary reasons for study
exclusion.

Figure 2.

Search, inclusion, exclusion, flow diagram
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Table 1.

Reasons for Study Exclusion

Study Characteristics
The 24 studies were published over a period of 18 years (2001—2019). Eleven
(11/24) focused on PCa initiation (Supplemental Table 1a), while thirteen (13/24)
focused on PCa progression (Supplemental Table 1b). All of the studies were randomized
control trials. The study designs varied, with (2/24) using a crossover design, and (1/24)
using a 3x3 factorial design. All randomized control trials had some concern for risk of
bias as per the Cochrane tool for assessing risk of bias (i.e., “high risk” or “unclear risk”)
(Supplemental Table 3ab). None of the studies reported any adverse events from the
study interventions.
Of the studies focusing on PCa initiation, many (5/11) of them administered
lycopene only through capsule supplementation, with most doses ranging from 2mg35mg daily. Of the studies focusing on PCa initiation that administered only lycopene via
supplementation (3/5) found that lycopene was able to inhibit initiation of PCa. Four
(4/11) studies administered lycopene in addition to other supplements. These
supplements included soy, isoflavones, lycopene, silymarin, antioxidants and
multivitamins. From the studies which administered lycopene with other supplements, 2
out of 4 found that lycopene was able to inhibit development of PCa in combination.
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Two studies evaluated a form of nonpharmacologic therapy. One study
implemented an intervention consisting of individual sessions where diet and physical
activity were discussed, as well as twelve 2.5-h group sessions conducted weekly over
the first three months of involvement. Positive health changes in a number of lifestyle
parameters were observed, and PSA levels were maintained. The other study
implemented a dietary supplement of whole tomatoes with a weekly Motivational
Telephone Counseling. Results from this study have not been published but was included
due to completed study enrollment.
Of the research focusing on PCa progression, the majority (8/13) of studies
administered lycopene solely through supplementation, with dosages ranging from 1560mg daily or twice daily. The studies focusing on PCa progression that administered
lycopene via supplementation (3/8) found that lycopene was able to decrease initiation of
PCa. Five (5) other studies that administered lycopene via supplementation did not have
published results. Four (4/13) studies administered lycopene in addition to other
supplements. These additional supplements included vitamin E, selenium, Vitamin D3
Green Tea Extract, oleoresin extract and verum. From the studies that administered
lycopene with other supplements, only 1 out of 4 studies found that the supplemented
group had fewer diagnoses of PCa. 2 studies did not have results published but was
included due to completed enrollment. One study administered lycopene solely through
diet. Participants were given a dietary supplement of tangerine tomato juice or dietary
supplement of red tomato juice vs control. The results of this study did not specify dosage
or results due to unpublished data.
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Timing of Interventions
All of the studies focusing on PCa initiation had vastly different time period of
interventions, ranging from intervention after rising PSA either before (3/11) or after
definitive treatment for PCa (3/11), diagnoses of high-grade prostatic intraepithelial
neoplasia (HGPIN) (4/11) and benign prostatic hyperplasia (BPH) (1/11). Interventions
administered before treatment with rising PSA levels showed (2/3) the majority did not
affect PCa initiation. 1 study had no result due to unpublished data. When intervention
was performed after treatment with rising PSA levels showed (3/3) inhibitory effect on
PCa initiation. Of the studies administering interventions with a diagnosis of high-grade
prostatic intraepithelial neoplasia (HGPIN) (3/4) found no effect on PCa initiation. The
one study administering interventions with a diagnosis of BPH (1/1) found that
intervention had an inhibitory effect on PCa initiation. Overall, 6 of the 11 showed that
lycopene was able to inhibit PCa initiation, 1 of them did not have published results. All
of the studies focusing on PCa progression had roughly the same length of intervention.
Patients from all studies had been previously diagnosed with PCa (13/13). Of these
studies, (3/13) found an inhibitory effect on progression, while (3/13) showed no
inhibitory effect, and (7/13) did not have published results.

Outcome Measures
In the studies for PCa initiation the most common outcome measure used was
PSA levels (7/11), other primary outcome measures included randomization and
intervention feasibility, serum lycopene levels and International Prostate Symptom Score
(IPSS). Secondary outcomes included serum lycopene levels, PSA levels, lifestyle
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changes, and survival. The duration of these outcome measures ranged from 4 weeks to 1
year, with the most common duration being 6 months (6/11).
Of the 13 studies looking at PCa progression, the most common (5/13) primary
outcome was PSA levels. Other primary outcomes included ICG/COX gene expression,
serum lycopene, global gene expression, and tumor size. Secondary outcomes included
recruitment and randomization, PSA levels, global gene expression, LH, testosterone, 5
alpha DHT levels. The timing of these outcome measures ranged from 3 weeks to 3
months, with the most common duration being 3 weeks (5/13).
Cohort Studies, Case-control Studies, and Cross-Sectional Studies (Lycopene and
PCa)
Search and Selection
The initial database search identified 1768 studies relevant to PCa and lycopene.
Most of the studies (1,577) (Fig 1) were excluded during the relevance screening
secondary to 1) uniform form of measurement* for evaluating the risk of PCa/current
status of PCa in patients, 2) missing intervention or control arm, or 3) no outcome
measure of PCa. A full manuscript review was performed on the remaining 191 papers,
resulting in 33 papers included for final analysis. Table 2 displays the primary reasons for
study exclusion.
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Table 2.

Reasons for Study Exclusion

Study Characteristics
32 studies published over a period of 20 years (1999-2019). Of these 29 studies,
the majority of them were quasi-experimental studies (13) [n=358] and case-controlled
studies (10) [n=11,261]., followed by cohort studies (8) [n=120,845], cross-sectional
studies (1) [n=3,927], and case control studies (1) [n=216] (Supplemental Table 2). All
studies had some concern for risk of bias as per the bias tool created for assessing risk of
bias (i.e., “high risk” or “unclear risk”) (Supplemental Table 4). None of the studies
reported any adverse events due to the interventions.

Quasi-Experimental Trials
Study Characteristics
Of the 13 quasi-experimental studies, (5/13) focused on PCa initiation and the
majority (8/13) focused on PCa progression (Supplemental Table 2d and 4d). Of the
studies focusing on PCa prevention, there was some heterogeneity of interventions. The
two most common forms of intervention were lycopene capsules (2/5) and lycopene
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administration through diet (tomato paste) (2/5). Dosage of lycopene capsules ranged
from 20mg-120mg. One (1/5) study used an intervention of herbal supplements which
contained lycopene. Of the studies administering lycopene through capsules and herbal
supplements, (2/5) of them did not report an inhibitory effect on PCa initiation. One study
did not have published results yet but had completed enrollment.
Of the (8/15) studies focusing on PCa progression, all (8/8) studies administered
lycopene through supplementation capsules. The most common dose was 15mg (3/8)
once or twice daily, followed by 10mg/day (2/8) and 30 mg of lycopene per day (1/8).
Two (2/8) studies gave supplemental lycopene with the addition of docetaxel. Of the
studies administering only lycopene through supplementation, the majority (4/6) of them
reported an inhibitory effect on PCa progression. Two studies did not have published
results yet but had completed enrollment.

Timing of Interventions and Duration of Study

Of the studies focusing on PCa initiation, timing of intervention ranged from with
elevated PSA (2/5), a histological diagnosis of benign prostate hyperplasia (1/5), or
HGPIN (1/5), and biochemically relapsed PCa (1/5). Given that the timing of
interventions varied and the limited number of studies, the results did not yield any
information regarding which timing of interventions that was most beneficial.
Of the studies focusing on PCa progression, timing of interventions ranged from
patients with already diagnosed with PCa (3/8) and patients who had progressed to
androgen-independent PCa (5/8). Studies just focusing on patients with diagnosis of PCa
found that (2/3) were able to affect PCa progression. One study did not have published
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results yet but had completed enrollment. Studies investigating androgen-independent
PCa, 2 out of 5 found that lycopene was not able to affect PCa progression. 1 study did
not have published results yet but had completed enrollment. Overall, (4/8) found that
lycopene had the capability of inhibiting PCa progression, (2/8) studies did not have
published data.

Outcome Measures
All studies focusing on PCa initiation used PSA levels (4) as the primary outcome
measures. Secondary outcome measures include serum lycopene levels (2), PSA in
relation to the differing modes of lycopene consumption (1), and changes in testosterone
or dihydrotestosterone (1). The duration of these studies were 2 months - 1 year, with the
most common duration being 3 months (2).
There was not much heterogeneity in outcome measures used in monitoring PCa
progression with most of the studies (6/8) used PSA serum levels to determine PCa
progression, while the remaining 2 studies used PSA levels as a secondary outcome.
Duration of intervention ranged from 3 weeks to death, with the most common duration
being 6 months (4).

Cohort studies
Study Characteristics
Of the 7 cohort studies, all were prospective focusing on PCa initiation
(Supplemental Table 2b and 4b) used previous cohort data already collected. These data
sets included the Health Professionals Follow-Up Study (2/7) Cancer Prevention Study II
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Nutrition Cohort (1/7), Adventist Health Study-2 (1/7) the Prostate, Lung, Colorectal, and
Ovarian Cancer Screening Trial (1/7) and the PROCOMB trial (2/7). 3 found that
administration of lycopene was able to inhibit PCa initiation, 2 found that there was
neither a supporting or dangerous role of lycopene, and 2 found that lycopene “may” play
a role in reduced risk of PCa.

Follow Up and Attrition Rates
Of these studies the most common primary outcome measure was diagnosis of
PCa or death during follow up. The most common type of follow up was a diet and
lifestyle questionnaire (3/7), biopsy and monitoring PSA levels (1/7) PCa specific
mortality (1/7), international prostate symptoms score (1/7) and tumor tissue microarray
(1/7). The duration of the studies ranged from 2 years to 23 years.

Case Controlled Studies
Study Characteristics
There were 10 case-controlled studies with four of them used a nested case
control study design, 4 used a population-based case control study design, and 2 used a
hospital-based case control study design. Most (9/10) were done in a retrospective
manner, and 1 was done in a prospective manner (Supplemental Table 2a and 4a).

Selection of Cases and Controls
Within the hospital and population-based case controlled-studies, there was a
heterogeneity of locations used for patient populations. These locations included Iran,
Greece, North Carolina, Texas, New York, Arkansas, and Scotland. The nested case
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control studies used previous trial data, including data from the Prostate, Lung,
Colorectal, and Ovarian Cancer Screening Trial (1/4), the Prostate Cancer Prevention
Trial (1/4), a previous cohort involving Wittenoom crocidolite mine and mill (1/4), and
Physicians Health study (1/4). The Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial, the Prostate Cancer Prevention Trial and Physicians Health study were
RCT, while the cohort involving Wittenoom crocidolite mine and mill was a cohort
study.

Matching
All case control studies were investigating PCa initiation. Since all studies were
case control studies, they were focusing on PCa risk, by comparing a control group
(without PCa) to a case group (with PCa). All population-based and hospital-based case
control studies matched case groups to controls in the same geographic area, age range,
and time. There were two (2) hospital-based case control studies, and both (2/2) found
that lycopene is capable of inhibiting PCa initiation. There were four (4/10) populationbased case control studies analyzed and all (4/4) found that lycopene reduced PCa risk.
Three of the nested case control studies used randomization and one (1/3) used presence
of PCa to determine controls and subjects.

Data Collection
There was no heterogeneity of outcome measures. Most of the case control
studies d used a food frequency question, sociodemographic data, and detailed histories
of smoking, alcohol, and family history of PCa (7/10). In addition to this data, some
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studies administered plasma analyses (4/10) and used this data to review PSA and IGF-1
levels. Given the retrospective design of most the case control studies, the timing of
outcome measures did not vary much; most studies conducted a one-time interview as
well as a structured questionnaire. The nested case control studies conducted a follow up
between 5-13 years.

Cross sectional Studies
Study Characteristics
There was only one cross sectional study that met all inclusion criteria. The study
was conducted in 2010 which reviewed the association between serum vitamin A and
carotenoid levels in relationship to PCa markers. This study used the cross-sectional data
from the 2001–2006 National Health and Nutrition Examination Surveys (Supplemental
Table 2c and 4c).

Characteristics of the Data set
All men chosen from the National Health and Nutrition Examination Surveys had
been identified as high risk based on their PSA levels. The data used was from 3 annual
data sets from 2001-2006.

Data Collection
This study evaluated PSA levels and total lycopene in serum as the primary
outcome. This study found that serum lycopene levels were significantly associated with
PSA in the general population of US men.
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Case Studies
Study Characteristics
There were two case studies performed. One study focused on PCa initiation and
the other on progression. One cohort consisted of patients with localized prostatic
adenocarcinoma on active surveillance, and the other used only the controls from a
previously performed case control study (Supplemental Table 2e and 4e).

Follow Up and Attrition Rates
The study focusing on PCa initiation had a primary outcome of determine dietary
risk and a secondary outcome of IGF-1 levels. The measures used to determine the
primary outcome were sociodemographic data, histories of smoking, alcohol, and coffee
consumption and a validated food-frequency questionnaire. Blood samples were also
taken to measure serum IGF-1 levels. Since this data was collected in a case control
method, there was no follow up and data collected consisted of a one-time interview.
The case study focusing on PCa progression had a primary outcome of time to
disease progression defined as either histologic progression on repeat biopsy or radical
treatment for PSA progression. Secondary outcomes were time to histologic disease
progression and PSA velocity. For this study, follow up was a medium of 2.5 years.

Outcome
The results of these two studies are contradictory with the study focusing on
progression stating that lycopene deficiency is the strongest known dietary risk factor for
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PCa, while the study focusing on progression reported that serum concentrations of
micronutrients, antioxidants and vitamins do not prevent disease progression.
Randomized Control Trails (MedD and PCa)

Search and Selection
The initial search for studies related to PCa and the MedD yielded 289 studies,
most of them (284) were excluded during the relevance screening (Fig 2). Studies were
excluded during the relevance screening secondary to 1) uniform form of measurement*
for evaluating the risk of PCa/current status of PCa in patients 2) missing intervention or
control arm, or 3) no outcome measure of PCa. A full manuscript review was performed
on the remaining 5 papers, resulting in only 1 paper included for final analysis with a
total of 23 subjects (Supplemental Table 5). Table 3 displays the primary reasons for
exclusion. All studies had some concern for risk of bias as per the Cochrane bias tool c
(i.e., “high risk” or “unclear risk”) (Supplemental Table 6). None of the studies reported
any adverse events from the interventions.

Figure 2.1.

Search, inclusion, exclusion, flow diagram
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Table 3.

Reasons for Study Exclusion

Study Characteristics
This RCT focusing on PCa progression was published in 2020 and was a pilot
randomized control. There was no heterogeneity of interventions tested. This study used a
nonpharmacologic therapeutic intervention consisting of either 12-week administration of
the MedD (individualized by a dietitian) with six nutrition consults or usual care. The
findings of this study were that the MedD is safe and feasible and has the potential to
improve CRF and quality of life in overweight men treated with ADT compared to usual
care.

Timing of Interventions
Since there was only one RCT for PCa and the MedD, there was no variance in
timing of intervention. All men had a confirmed PCa and must be receiving ADT for at
least 3 months.

Outcome Measures
There was no heterogeneity in outcome measures. The primary outcomes of this
study were Cancer-related fatigue (CRF) and quality of life. With secondary outcomes of
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body mass/composition and interleukin (IL)-6 and IL-8 concentrations and feasibility and
safety. The findings of this study are that the MedD has the potential to improve CRF and
quality of life in overweight men treated with ADT compared to general care.

Cohort Studies, Case-controlled Studies, and Cross-Sectional Studies (MedD and PCa)

Study Characteristics
21 studies published over the last 17 years (2005-2021). Of these studies, 12
looked at PCa initiation, while 9 studied PCa progression (Supplemental table 5). The
majority of these studies were case-controlled studies (9) [n=14,804], followed by cohort
(7) [n=1,606,342] studies, and the remaining (3) studies were experimental studies
[n=63] and (2) case only studies [n=3,172]. There were no cross-sectional studies. Table
4 explains primary reason for study exclusion. All studies had some concern for risk of
bias as per the bias tool created for assessing risk of bias (i.e., “high risk” or “unclear
risk”) (Supplemental Table 7). None of the studies reported any adverse events due to the
study interventions.

Table 4.

Reasons for Study Exclusion
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Cohort Studies
Study Characteristics
There were 9 cohort studies that met all inclusion criteria and no exclusion
criteria. There were (7/9) that focused on PCa initiation and (2/9) that focused on PCa
progression, most (5/9) were prospective while the remaining (2/9) were retrospective
(Supplemental Table 5 and 7c).
Of the prospective studies that focused on PCa initiation, most (4/5) studies used
previous cohort data. This data included, the National Institutes of Health (NIH)-AARP
Diet and Health Study (1), Uppsala Longitudinal Study of Adult Men cohort (1)
Netherlands Cohort Study (1), and the NutriNet-Sante cohort (2009–2017) (1). Of the
studies that were done in a prospective manner using previous cohort data focusing on
PCa initiation, only (1/5) studies found that the MedD was successful in inhibiting PCa
initiation.
One (1) prospective study focusing on PCa progression established its own cohort
using subjects that were newly diagnosed with PCa and on active surveillance (AS). The
results from this study indicate that the Med is associated with lower risk of Gleason
grade increase. The results of this study concluded that the Med is associated with a
lower risk of Gleason grade progression in men on AS.
Two (2) studies focusing on PCa initiation were performed in a retrospective
manner. Both studies used previously collected cohort data, this data included, the Swiss
National Cohort (1) and an Italian case-control study (1). Both (2/2) of these studies
found that pre-diagnostic adherence to a MedD was beneficial to PCa mortality.
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Outcome Measures
Of the studies focusing on PCa initiation the most common primary outcomes
were, Alternate Mediterranean Diet Score (aMED) (2/7), PCa mortality (2/7), modified
Mediterranean Diet Score (mMDS) (1/7) and initiation of PCa (1/7). Secondary outcomes
included, Mediterranean Diet Score (MDS), carbohydrate high protein score and physical
activity.
The two studies that used a primary outcome of aMED score found that aMED
score was not related to total PCa or advanced PCa risk. The two studies who used PCa
mortality as a primary outcome found that adherence to the MedD had protective role on
PCa mortality. Overall, (3/7) cohort studies focused on PCa initiation found that
adherence to a MedD was beneficial to decrease PCa initiation.
The two studies focusing on PCa progression used Gleason score and disease
progression as the primary outcome with a secondary outcome of constructed MedD
score and lower overall mortality. One (1/2) study found that the MedD is associated with
lower risk of Gleason grade increase, while the other (1/2) found that the Med-Diet score
was not associated with disease progression.

Timing of Follow up and Attrition Rates
The duration of studies ranged from 2-20 years, other studies followed up with
patients at varying ages, elective study removal, and death. Study follows ups ranged
from every 6 months to every 4 years.
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Case Control Study
Study Characteristics
There were 9 case control studies that met all inclusion and no exclusion criteria.
All of these studies were conducted in a retrospective manner. The majority of these
studies (5/9) used population-based controls, while the remaining (4/9) used hospitalbased controls (Supplemental Table 5 and 7a).

Selection of Cases and Controls
Within the hospital and population-based controls there was a heterogeneity of
locations used for patient populations, these locations included Iran (2/9), Italy (3/9),
Spain (3/9), and Sweden (1/9). Most (7/9) studies conducted their own case control study
except, (2/9) used previously collected data. This data includes MCC-Spain (MulticaseControl Study on Common Tumors in Spain and Cancer of the Prostate in Sweden
(CAPS) study.
Within the studies that used hospital based and population-based controls, the
majority [hospital based (3/4), population based (4/5)] found that found that MedD was
able to inhibit PCa initiation.

Matching
All case control studies were investigating PCa initiation, due to the nature of
these studies. Since all studies were case control studies, they were focusing on PCa risk,
by comparing a control group (without PCa) to a case group (with PCa). All population
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based and hospital based designed case control studies matched case groups to controls in
the same geographic area, age range, and time.
Since two of the studies used previous data, matching was performed either
through simple regression models which included the matching factors: age and region of
residence or frequency matching by age and gender.

Data Collection
There was not a heterogeneity of outcome measures used, all of the case control
studies gathered used a food frequency question, sociodemographic data, detailed
histories of smoking, alcohol, and family history of PCa (9/9). In addition to this data,
some studies used PSA levels and Gleason scores (1/9), MedD score (3/9) and physical
activity questionnaires (3/9).
Given the retrospective design of most the case control studies, the timing of
outcome measures did not vary much; most studies conducted a one-time interview as
well as a structured questionnaire. Overall (7/9) found that the MedD is capable of
inhibiting PCa initiation.

Case Only Studies
Study Characteristics
There were two (2) case only studies, both studies focused on PCa progression.
These studies used cases from the North Carolina Louisiana Prostate Cancer Project
(PCaP) and the Health Professionals Follow-up Study. These cases consisted of subjects
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with histologically confirmed adenocarcinoma of the prostate and men diagnosed with
nonmetastatic PCa (Supplemental Table 5 and 7b).

Follow Up and Attrition Rates
Both primary outcomes included disease progression. The methods used to
determine primary outcome included Gleason sum, and prostate-specific antigen (PSA)
level, reported medical diagnoses, medications, height, weight, ethnicity, and lifestyle
factors and completed a validated semi-quantitative food-frequency questionnaire (FFQ).
Secondary outcome measures included MED scores and Dietary Approaches to Stop
Hypertension score (DASH scores).
The data collected from the North Carolina Louisiana Prostate Cancer Project
(PCaP) did a one-time data collection since its study design was a case study. The data
collected from the Health Professionals Follow-up Study used data from over a 24-year
period (1986 - 2010) and did a follow up every 2 years. The average questionnaire
response rate is 96%.

Outcome
These studies reported contradictory results, one stating that the higher intake of a
Mediterranean-style diet may reduce the odds of highly aggressive PCa, while the other
stated that the MedD score was not associated with risk of advanced PCa or disease
progression.
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Quasi-Experimental Studies
Study Characteristics
Of the three (3) quasi-experimental studies, all of them focused on PCa
progression. All studies had an intervention of administration of a Mediterranean style
diet (3/3) while (1/3) added the addition of a nutritional prostatitis formula (Peenuts®) as
a supplement (Supplemental Table 5 and 7d).

Timing of Interventions and Duration of Study.
All men in these studies (3/3) had already been diagnosed with PCa and had a
Gleason score between 5-7. Study duration ranged from 3- 84 months with the most
common duration being 3 months (2).

Outcome Measures
There was not a heterogeneity of outcomes measures used, all studies (3/3) used
PSA as a primary outcome and (2/3) studies had secondary outcomes of C-reactive
protein and DNA damage. All of these studies reported that the MedD intervention was
beneficial to patients with PCa.

Cross Sectional Studies
There were no cross-sectional studies that met all inclusion criteria and no exclusion
criteria.
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DISCUSSION
This report was a systematic review of both clinical and observational research
investigating and testing interventions aimed at preventing and inhibiting PCa
progression. The objective was to collect, categorize and analyze current literature to
determine if lycopene or the MedD was capable of preventing or inhibiting progression
of PCa. This review collected both observational studies and RCT. Different study types
have different strengths of conclusion, with the highest being meta-analysis/systematic
reviews and lowest being case reports. After reviewing and analyzing previous metaanalysis focusing on lycopene [43-51] and the MedD [62-66] on PCa, there seemed to be
conflicting results regarding whether lycopene or the MedD was able to inhibit initiation
or progression of PCa. Since the previous meta-analyses have led to different
conclusions, the question is raised as to why. Due to these conflicting results both
observational and clinical research was included in this systematic review to have a larger
study population and try to identify any trends that may be present. The purpose of this
was to expand the data pool so that a more precise conclusion could be reached. Since the
results collected from observation studies (ex. cohort studies, case-control studies, and
cross-sectional studies) did not show any consistent trends, and observational studies
have the weakest strength of conclusion, the discussion will be primarily focusing on and
analyzing the results received from the randomized clinical trials.
There have already been 9 [ 43-51] meta-analyses or systematic reviews focusing
on Lycopene and PCa. The biggest difference between the current review and previous
ones is the quantity and characteristics of the studies used. Most (5/9) [33,44,45,47,48,51]
of the previous analyses only used observational studies (cohort, case-control, and nested
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case-control), while the remaining (4/9) [43,46,48,49] analyses used a combination of
RCT and observational studies (2/4) [49,48], or ONLY RCT (2/4) [43,46]. Even though
meta-analyses and systemic reviews have the highest strengths of conclusion, previous
meta-analyses and systemic reviews using solely observational data have led to
conflicting results. One study [45] found that both higher dietary and circulating lycopene
concentrations are inversely associated with PCa risk, while another found that only
lycopene intake reduced PCa risk, and not lycopene circulating concentrations [50]. The
reason for these discrepancies could be the use of observational studies. This speculation
is further supported when comparing these studies to the two studies that used only RCT,
since they both had consistent conclusions. One reason for this could be that using data
collected from RCT have with the highest level of evidence of conclusion. Overall, of
(7/9) studies using observational data, 5 out of 7 focused on PCa initiation while 2 of the
7 focused both initiation and progression. Of the studies focusing on only initiation (4/5)
found that lycopene was beneficial in decreasing PCa initiation. From the studies
focusing on both initiation and progression, both (2/2) found that lycopene was able to
decrease risk but did not affect progression. Of the two (2/9) studies analyzing ONLY
RCT, both assessed the effectiveness of lycopene for the prevention of PCa and found
that there is insufficient evidence to either support or refute the use of lycopene for the
prevention of PCa.
When further breaking down the methodology used in the previous studies, the
most common form of analysis was risk ratios and/or confidence intervals (7/9). Odds
ratio (1/9), I2 metric, and Cochran’s Q test (1/9). There was no association between the
types of statistical test done on the outcomes. When comparing the current systemic
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review with previous, it makes the most sense to first compare it to the study done by Ilic
D. et al [43] who also only analyzed RCT. The largest difference between these two
studies is the number of studies that met all inclusion and exclusion criteria. Ilic D et al.
only included studies with men who had NOT been previously diagnosed with PCa in
addition to interventions aimed at increasing lycopene intake. Therefore, no
pharmacological therapies were included. Ilic D et al [43] analyzed 3 RCT studies, while
this review analyzed 24 studies (the 3 studies analyzed by Ilic were included in this study
as well).
The second difference between the two studies is the risk of bias assessment. Both
studies used the Cochrane Risk Bias Tool to assess the risk of bias, but Ilic D et al. [43]
was able to use two independent reviewers to assess bias, while this review only had one
reviewer. The lack of independent reviewers in this systematic review could lead to
observer bias due to a lack of interobserver agreement (IOA). Even though Ilic D et al did
not state the amount of Interobserver Agreement between the two independent
researchers, the risk of bias is less due to the nature of the assessment.
The last difference between these two studies is the statistical analysis performed.
Ilic D et al. [43] performed a Risk ratio (RR), with 95% confidence intervals (CI) to
demonstrate the dichotomous outcomes, while this review did not perform any statistical
tests. The RR results received from Ilic D concluded there is a non-significant association
between the variables. Relative risk was not calculated in this review since there was a
heterogeneity of interventions and patient groups. Therefore, the risk ratio would not be
statistically significant. Even though there are notable differences between the
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methodologies used, the conclusion reached by Ilic D et al [43] agrees with the
conclusion of this review.
The other previous systematic review [46] performed only using RCT focused on
preventative strategies for men with high-grade prostatic intraepithelial neoplasia
(HGPIN). As with the review performed by Iliac D et al. [43] the largest discrepancy
between the two studies was the criteria for study selection. Kang Cui et al. only included
studies with men who had been diagnosed with HGPIN and included chemo-preventive
treatment options, such as Dutasteride, flutamide, toremifene, selenium, green tea
components, lycopene, and natural food products combination. Therefore, no
nonpharmacologic therapies were included. Another difference in study selection was the
number of studies used. Kang Cui et al. [46] analyzed 13 RCT studies, while this review
analyzed 24 studies. Of the 13 studies analyzed by Kang Cui et al. [46], many (5/13) of
them were included in this review as well. The remaining (8/13) studies were not
analyzed in this review due to a focus on toremifene (2/8), selenium bicalutamide (2/8),
green tea catechins (1/8), dutasteride (1/8), and flutamide (1/8).
The second difference between the two studies is the risk of bias assessment. Both
studies used the Cochrane Risk Bias Tool to assess the risk of bias. But Kang Cui et al.
[46] was able to use three independent reviewers to assess bias, while this review only
had one reviewer. The lack of independent reviewers in this systematic review could lead
to observer bias due to the lack of IOA. Even though Kang Cui et al. [46] did not state the
amount of IOA between the two independent researchers, the risk of bias is less due to
the nature of the assessment.
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The last difference between these two studies is the statistical analysis performed.
Since the data collected by Kang Cui et al. [46] did not have much heterogeneity, a metaanalysis was performed. The statistical tests performed were fixed-effects model and
confidence intervals. Due to the broad inclusion and exclusion criteria used in this
review, there was a heterogeneity of different interventions, follow-up methods, and
outcome measures used for measuring both PCa initiation and progression. Therefore, it
would not be possible to perform a meta-analysis to quantitatively analyze the data.
Although there were differences in methodology and analysis, the results received by
Kang Cui et al. [46] stated that lycopene did not show significant clinical benefits in
patients diagnosed with HGPIN. Therefore, the results of analysis by Kang Cui et al. [46]
agree with the conclusion of this review.
There were 24 studies that met our inclusion criteria for the question of whether
lycopene is able to inhibit PCa initiation or progression. 11 of the 24 focused on
initiation, and the other 13 focused on progression. The results of this review suggest that
there is insufficient evidence to either support or refute the use of lycopene for the
prevention or inhibition of progression of PCa. There was a heterogeneity of different
interventions, follow-up methods, and outcome measures used for measuring both PCa
initiation and progression. Therefore, it would not be possible to perform a meta-analysis
to quantitatively analyze the data. The most beneficial way to further analyze this
connection would be to investigate potential mechanisms of lycopene.
One common theme for intervention was lycopene administration through
supplementation. Of the studies focusing on PCa initiation, the majority (5/11) of studies
administered lycopene only through capsule supplementation. Of these five studies, the
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majority (3/5) found that lycopene was able to decrease initiation of PCa. No studies that
were studying PCa initiation, administered an intervention through diet.
Of the RCT collected that focused on PCa progression, the majority (8/13)
administered solely lycopene supplements. Five (5/13) of these studies had only
unpublished data, the remaining three (3/8) studies found that lycopene was able to
inhibit the progression of PCa. One study administered lycopene only through diet
(tangerine tomato juice or a Dietary Supplement of red tomato juice vs control) but the
results of this study have not been published yet. It is possible that the full beneficial
effects from lycopene can only be obtained when it is consumed through the diet, rather
than as supplements [74]. There was no clear consensus as to whether the dietary
intervention was more effective than supplementation. Since many of the studies that
used dietary intervention have not yet been published, this review is not able to conclude
that dietary intervention is more beneficial than supplementation.
Another common intervention was lycopene with the addition of other
supplements. Of the RCT focusing on initiation, (4/11) studies administered lycopene
with other supplements. From these four studies, half (2/4) found that lycopene was able
to inhibit the initiation of PCa. Of the studies focused on PCa progression, four (4/13)
administered lycopene with other supplements. There were two (2/4) studies that had
unpublished data, but from the remaining two studies, half (1/2) found that lycopene was
able to inhibit the progression of PCa. These additional supplements included vitamin E,
selenium, vitamin D3, green tea extract, oleoresin extract, verum, soy, isoflavones,
silymarin, antioxidants (unspecified), and multivitamins. Administering lycopene in
addition to other various supplements did not seem to affect the outcome, but this could
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be due to the limited quantity and quality of studies done. Since the results did not reach a
consensus on whether lycopene in addition to other supplements affects PCa, we cannot
agree or disagree with previous research which has found that various dietary fats (ex.
Olive oil) are capable of increasing lycopene bioavailability (aka serum lycopene) [7476]. The bioavailability of lycopene is directly related to its chemical structure. Lycopene
is very hydrophobic, and trans-conformation most common form. Due to its
hydrophobicity, the addition of dietary fats (ex. Olive oil) may help increase digestion
and absorption and therefore increasing its bioavailable [52, 77]. Another factor to
consider when trying to determine which form of lycopene is most beneficial is whether
it is cooked. Cooking can transit lycopene to a cis-conformation, which can be better
absorbed [77].
There have been two previous RCT trials done studying the effect of
bioavailability of lycopene with dietary fats [52,77]. These two trials came to varying
results, with one finding that the addition of olive oil during tomato cooking greatly
increased the absorption and bioavailability of lycopene when compared to subjects
consuming just cooked tomatoes without olive oil [52]. While the other study found that
when comparing a high lycopene diet with addition of olive oil vs. a diet high in
carbohydrate and low in olive oil, the two diets appeared to have a similar effect on
bioavailability of lycopene [77]. Since both studies used cooked tomatoes, therefore the
configuration of lycopene most likely did not play a factor in the results. One potential
reason for this discrepancy could be the type of lycopene administered, with one study
using whole tomatoes and the other using tomato soup and tomato paste. Even though
there were not enough RCT collected to categorize the results based on type of dietary
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intervention, based on the studies collected, the relationship between serum lycopene
levels and its effect on PCa initiation and progression are somewhat conflicting as to
whether or not serum lycopene is beneficial to reduce PCa risk/aggressiveness [28,40,50].
From the studies used, the most common measurement of PCa initiation or
progression was prostate-specific antigen levels (PSA) levels. In the RCT studies for PCa
initiation, most (6/11) had an outcome measure of PSA levels. Of these six studies, half
(3/6) found that lycopene was able to either decrease or stabilize PSA levels. Of the 13
RCT studies looking at PCa progression, the most common (5/13) primary outcome was
also PSA levels. Two studies (2/5) did not have results due to unpublished data. Of the
three remaining (3/5) studies, (2/3) concluded that lycopene was beneficial in affecting
PCa progression. One limitation in assessing whether PSA is an accurate measure for
dietary intervention is the sample size. All studies had very small sample sizes and
therefore none can be considered a statistically significant sample size. Due to the
heterogeneity of interventions used and subject criteria, one cannot combine subjects
from different studies r to create a larger sample size. The findings from this systematic
review are not able to either agree or disagree with previous research findings, which
state that the PSA levels are not able to accurately predict the severity of cancer and that
PSA levels are minimally affected by diet [78].
There was very few large scale, high-quality studies available regarding PCa and
the MedD. All previous meta-analyses and systemic reviews have only been done using
observational data and therefore lacking high quantity RCT. The most recent metaanalysis done in 2019 [66] found that the MedD pattern has no relationship with PCa risk,
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and the results of this study are contradictory to previous meta-analyses done
[62,64,65,79], which conclude that the MedD is beneficial in preventing PCa occurrence.
Further analyzing the methodology of the previous meta-analyses/systemic
reviews found one (1/5) [64] study that used both observational and RCT, but the RCT
did not pertain to PCa. Of the 5 previous meta-analyses/systemic reviews, (3/5) found
that the MedD was capable of reduction in PCa risk [62-64]. While the remaining (2/5)
[67, 69] found that MedD pattern has no relationship with PCa risk. Some reasons for
these discrepancies could be due to methodological approach, author judgments and
performance, and differences in inclusion and exclusion criteria [80]. Since none of these
studies used RCT in their analysis, it is difficult to compare this systemic review with
previous.
Since there was only one (1) [81] RCT that met all inclusion and no exclusion
criteria there is not enough data to conclude that MedD affects either PCa initiation or
progression. The primary outcome measures used were a Functional Assessment of
Chronic Illness Therapy (FACIT)-Fatigue scale (FACIT-F) and quality of life [FACITGeneral (FACIT-G)]. All of these forms of assessments have been proven to be both
valid, sensitive, and a very low bias [82]. Since the primary results received by Brenton J.
Baguley et al. [81] stated that the intervention improved Cancer-Related Fatigue (CRF)
and quality of life in overweight men treated with ADT compared to regular care, this
review would recommend the use of nutrition consultations with an accredited practicing
dietitian as well as an individualized MED recommendation. No other RCT either
pertaining to lycopene or the MedD used CRF or quality of life as primary or secondary
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outcomes, therefore a comparison between these results to previous research cannot be
carried out.
Secondary outcomes from this study [81] included body mass/composition and
interleukin (IL)-6 and IL-8 concentrations measured at baseline, 8-weeks, and 12 weeks.
The results of these secondary outcomes show that the intervention group showed
significant reductions in serum IL-8 (ng/ ml) compared to the standard care group at 8weeks, but there was no further change in IL-8 at week-2. There were also no significant
differences in IL-6 between groups at any time point [81]. Since no other studies (RCT
and Observational) included in this review used IL-6 or IL-8 as primary or secondary
outcomes, a comparison between these results to previous research cannot be carried out.
Even though a comparison could not be performed, previous research has already
established that IL-6 and IL-8 concentrations are a reliable method with prognostic and
survival significance, with the ability to assess aggressiveness as well as bone metastasis
[83, 84]. The secondary results by Baguley et al [81] raising the question of is the MedD
able to quantitatively affect PCa. To answer this question, more RCT trials measuring IL6 and IL-8 levels will be needed.
There are several limitations to this systematic review. The main limitation is that
there were a limited number of intervention trials (Lycopene and PCa= 24, MedD and
PCa= 1) that have reported on either the effect of Lycopene and the MedD on PCa. In
addition, most of the included RCT studies were small (largest total n = 133) and all had
some concern for bias according to the Cochrane Collaboration’s tool for assessing the
risk of bias in clinical trials as well as the Rubric of Criteria created to assess bias in
observational studies. Therefore, the results of the included studies must be interpreted
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with caution, and the specific nature of potentially beneficial interventions remains
unknown. Interobserver agreement could not be measured for either the Cochrane
Collaboration’s tool or the Rubric of Criteria due to limited personal. The second
limitation was a very high degree of heterogeneity, since studies used various
interventions, clinical outcomes, and clinical scenarios. Given this heterogeneity, it was
only possible to perform a qualitative analysis of the current literature and to assess the
effects of certain interventions on any particular clinical outcome. Furthermore, different
clinical scenarios may respond to different interventions. Therefore, future research
should stratify study populations by clinical scenario and severity of illness. Third,
although multiple databases were used and there was no restriction for study inclusion,
and clinical trial registries were searched for unpublished studies, it remains possible that
pertinent studies were performed and either not published or not identified by the search
strategy used.
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APPENDIX
•

Must be logged into a PCOM email address

Supplemental Table 1ab: RCT focusing on Lycopene and PCa
https://drive.google.com/file/d/1BhVc0ewQKRxpXb77KInATRJt42j2Rik/view?usp=sharing
Supplemental Table 2: Observational Studies focusing on Lycopene and PCa
https://drive.google.com/file/d/1ra5UGHvbAG4JLWRXHB5vlAS4NXMf1uo5/view?usp
=sharing
Supplemental Table 3a: Cochrane Collaboration’s tool for assessing the risk of bias for
each included article regarding Lycopene and PCa Incidence
https://drive.google.com/file/d/1kj01f8LrlfCDVijdJquNpCU7OW6jIocF/view?usp=shari
ng
Supplemental Table 3b: Cochrane Collaboration’s tool for assessing the risk of bias for
each included article regarding Lycopene and PCa Progression
https://drive.google.com/file/d/1qOvaheL5DgmH9WBSosQ3YST2tBNRzIr0/view?usp=
sharing
Supplemental Table 4a: Rubric of Criteria for Lycopene and Case Control Studies
https://drive.google.com/file/d/1_SQ1uAVALUiA66rb6zdnk6_85BTHAdE/view?usp=sharing
Supplemental Table 4b: Rubric of Criteria for Lycopene and Cohort Studies
https://drive.google.com/file/d/1FEXN_IsHm4AXZMXtMeDsnwQ6wnC38owm/view?u
sp=sharing
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Supplemental Table 4c: Rubric of Criteria for Lycopene and Cross Sectional Studies
https://drive.google.com/file/d/1MDWiAti8ggtcewAf6QJxTHsM4xz7fEfa/view?usp=sha
ring
Supplemental Table 4d: Rubric of Criteria for Lycopene and Quasi-Experimental Studies
https://drive.google.com/file/d/18NBgwPHANMvSaWE1WKvX9FGJQcQoV3f1/view?u
sp=sharing
Supplemental Table 4e: Rubric of Criteria for Lycopene and Case Series
https://drive.google.com/file/d/1GWYqbUxwivnvhCwnwXY7XnWgdEX1FTRp/view?us
p=sharing
Supplemental Table 5: RCT and Observational Studies focusing on the MedD and PCa
https://drive.google.com/file/d/1JHJ5gp1TIF5wP1gDL_SZLq4xlv0utOT3/view?usp=sha
ring
Supplemental Table 6: Cochrane Collaboration’s tool for assessing the risk of bias for
each included MedD and PCa article
https://drive.google.com/file/d/1EjcExH3T8oQY7GdAiuBHEUlLzrCkp2zh/view?usp=sh
aring
Supplemental Table 7: Rubric of Criteria tool for assessing the risk of bias for each
included MedD and PCa article
https://drive.google.com/file/d/1iNRDJ2CjsRLTPwMHIt3GCTxVX7dWsHP4/view?usp
=sharing
Supplemental Table 8: References for all supplemental tables
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https://drive.google.com/file/d/1_qRpvrQM9chX04bfQ5nM8FCCJUUrZFJ4/view?usp=s
haring

